CEPI–Samsung Biologics Strengthen Global Vaccine Readiness

Industry Insights from Next Move Strategy Consulting

As global health systems prioritize preparedness for future epidemic and pandemic threats, a newly announced collaboration between the Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics marks a significant step forward in strengthening vaccine readiness. The partnership focuses on reinforcing manufacturing capabilities to ensure faster availability of vaccines and broader global access when new outbreaks emerge. Under the agreement, Samsung Biologics joins CEPI’s Vaccine Manufacturing Facility Network (VMFN), aligning its large-scale manufacturing expertise with CEPI’s mission to accelerate vaccine development and deployment, particularly for Low- and Middle-Income Countries (LMICs).

Building Scalable and Rapid Vaccine Manufacturing Pathways

Supported by an initial budget of up to US$20 million, CEPI will collaborate with Samsung Biologics to establish a scalable and rapidly deployable manufacturing process for recombinant protein vaccines. The initiative leverages Samsung Biologics’ mammalian cell-based production infrastructure, alongside its established quality and regulatory systems, to pre-position a ready-to-activate process that can be mobilized quickly in response to emerging viral threats. This approach is designed to give protein-based vaccines enhanced responsiveness in future outbreak scenarios, strengthening global preparedness.

Simulating Outbreak Response to Demonstrate Readiness

As part of the collaboration, Samsung Biologics will conduct a simulated outbreak response exercise using wild-type H5 influenza, a prototype pathogen recommended by the World Health Organization. The exercise will assess end-to-end capabilities, from antigen development through vaccine drug product manufacturing and supply. The simulation is expected to provide practical insights into the speed and robustness of large-scale recombinant protein vaccine production during an outbreak and support preparations for a generic regulatory submission dossier.

Expanding Equitable Access Through the VMFN

By joining CEPI’s global VMFN, Samsung Biologics will provide CEPI with guaranteed access to up to potentially 50 million vaccine doses in a future pandemic, along with up to one billion doses of drug substance that can be converted into finished vaccines. This arrangement prioritizes access for vulnerable populations in underserved LMIC regions, while also allowing Korea’s national vaccine needs to be addressed in line with CEPI’s Equitable Access Policy. The partnership also supports CEPI’s 100 Days Mission, which aims to enable the development of vaccines within 100 days of identifying a novel pathogen with pandemic potential by establishing pre-agreed, end-to-end manufacturing pathways for rapid scale-up.

Strategic Perspectives from Industry Leaders

CEPI highlighted that Samsung Biologics’ recombinant protein production scale and technical capabilities significantly strengthen its outbreak-response infrastructure. Samsung Biologics, in turn, emphasized its commitment to supporting a reliable and agile vaccine supply ecosystem and contributing to timely access to vaccines during urgent public-health situations. The collaboration also expands the geographical reach of CEPI’s VMFN, with Samsung Biologics becoming its first East Asian manufacturing partner, joining an existing network spanning Brazil, India, Indonesia, South Africa, and Senegal.

Next Move Strategy Consulting’s Viewpoint

According to Next Move Strategy Consulting, the CEPI–Samsung Biologics collaboration reflects a broader shift in the Vaccines Market landscape toward pre-positioned manufacturing capacity, distributed supply networks, and rapid-response readiness. By integrating advanced CDMO capabilities into a global preparedness framework, the initiative strengthens the resilience of vaccine supply chains and reinforces equitable access as a central pillar of future outbreak response strategies.

Reinforcing Global Vaccine Preparedness

As epidemic and pandemic risks continue to challenge global health systems, the partnership between CEPI and Samsung Biologics underscores the importance of coordinated, scalable manufacturing solutions. With a focus on speed, capacity, and access, the collaboration represents a meaningful advancement in ensuring that vaccines can be produced and delivered efficiently when new health threats arise.

Source: PR Newswire

Prepared by: Next Move Strategy Consulting